EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Δ9-tetrahydrocannabinol, a cannabis sativa–derived natural product, as a probe of endocannabinoid system plasticity in type 1 diabetes: a receptor-level, testable hypothesis

Wojciech Łukowski

Frontiers in Natural Products · 07.07.2026 · 5

DOI: 10.3389/fntpr.2026.1812441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Natural Products, online erschienen am 07.07.2026. Verfasst von Wojciech Łukowski. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes (T1D) is a chronic autoimmune disease in which receptor-level regulation of the endocannabinoid system (ECS) remains largely unmapped. While ECS perturbations have been extensively described in obesity and type 2 diabetes, a directed experimental interrogation of receptor adaptability in autoimmune diabetes is still lacking. Within the framework of natural-product pharmacology, plant-derived Δ 9 -tetrahydrocannabinol (Δ 9 -THC), the principal psychoactive constituent of Cannabis sativa L., provides a uniquely suitable experimental probe of this gap, owing to its partial CB1 agonism, high lipophilicity, oral bioavailability, and documented tolerability in chronic human exposure paradigms. This hypothesis-driven article advances a receptor-level testable framework in which chronic, dose-escalating oral Δ 9 -THC exposure is hypothesized to induce GRK2/3-mediated CB1 phosphorylation, β-arrestin–driven receptor desensitization, and a relative shift of ECS tone toward CB2-associated regulatory signaling. The framework integrates evidence on intestinal barrier dynamics, immune polarization, the blood–pancreas barrier as a structurally analogous ECS-sensitive interface, and β-cell metabolic plasticity, but is deliberately confined to receptor-level adaptations as the central, testable claim. Δ 9 -THC is introduced strictly as a purified plant-derived probe administered orally under controlled experimental conditions, not as a therapeutic candidate. Alternative pharmacological tools—including synthetic CB1 agonists and inhibitors of endocannabinoid degradation (FAAH, MAGL) — are explicitly acknowledged; however, Δ 9 -THC is positioned as the natural-product–compatible probe most aligned with the editorial scope of this article. By formalizing a set of falsifiable predictions in NOD mouse models, isolated islets, intestinal organoids, and human cross-sectional cohorts, this work converts an analogical and extrapolative literature into a discrete preclinical research agenda. The ECS-centred framework is explicitly framed as complementary to—not in competition with—established mechanistic axes in T1D pathogenesis, including HLA-associated genetic susceptibility, viral triggers, and β-cell intrinsic stress responses.

Zitieren

APA

Łukowski, W. (2026). Δ9-tetrahydrocannabinol, a cannabis sativa–derived natural product, as a probe of endocannabinoid system plasticity in type 1 diabetes: a receptor-level, testable hypothesis. Frontiers in Natural Products, 5. https://doi.org/10.3389/fntpr.2026.1812441

Vancouver

Łukowski W. Δ9-tetrahydrocannabinol, a cannabis sativa–derived natural product, as a probe of endocannabinoid system plasticity in type 1 diabetes: a receptor-level, testable hypothesis. Frontiers in Natural Products. 2026;5. doi:10.3389/fntpr.2026.1812441

BibTeX
@article{ukowski2026,
  author = {Łukowski, Wojciech},
  title = {Δ9-tetrahydrocannabinol, a cannabis sativa–derived natural product, as a probe of endocannabinoid system plasticity in type 1 diabetes: a receptor-level, testable hypothesis},
  journal = {Frontiers in Natural Products},
  year = {2026},
  volume = {5},
  doi = {10.3389/fntpr.2026.1812441}
}
Kostenlos starten →